FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800306622> ?p ?o ?g. }

• W2800306622 endingPage "106.e4" @default.
• W2800306622 startingPage "98" @default.
• W2800306622 abstract "Background & AimsAlthough proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always effective. We conducted a randomized phase 2 trial to determine the efficacy and safety of 2 doses of a budesonide suppository vs mesalamine suppositories vs combined budesonide and mesalamine suppositories for proctitis.MethodsWe performed a prospective, double-blind, double-dummy, multicenter trial in 337 patients with active proctitis to compare the efficacies of 4 different suppository treatments. Patients were randomly assigned to groups given 2 mg budesonide suppositories (2 mg BUS; n = 89 patients), 4 mg BUS (n = 79), 1 g mesalamine suppositories (1 g MES; n = 81), or the combination of 2 mg BUS and 1 g MES (n = 88). The study was performed from November 2013 through July 2015 at 36 study sites in Europe and Russia. The primary end point was the time to resolution of clinical symptoms, defined as the first of 3 consecutive days with a score of 0 for rectal bleeding and stool frequency.ResultsThe mean time to resolution of symptoms in the 4 mg BUS (29.8 days) and combination of 2 mg BUS and 1 g MES (29.3 days) groups resembled that of the standard 1 g MES treatment (29.2 days), but was significantly longer in the 2 mg BUS group (35.5 days). Furthermore, proportions of patients with deep, clinical, and endoscopic remission, as well as mucosal healing, were similar among the 1 g MES, 4 mg BUS, and combination therapy groups, but significantly lower in the group that received 2 mg BUS. No safety signals were observed, and the patients’ treatment acceptance was high (67%–85% of patients).ConclusionsIn a multicenter randomized trial, we found that the efficacy and safety of 4 mg BUS in treatment of active proctitis did not differ significantly from those of 1 g MES. Budesonide suppositories offer an alternative therapy to mesalamine for topical treatment of proctitis. Clinicaltrialsregister.eu no: 2012-003362-41. Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always effective. We conducted a randomized phase 2 trial to determine the efficacy and safety of 2 doses of a budesonide suppository vs mesalamine suppositories vs combined budesonide and mesalamine suppositories for proctitis. We performed a prospective, double-blind, double-dummy, multicenter trial in 337 patients with active proctitis to compare the efficacies of 4 different suppository treatments. Patients were randomly assigned to groups given 2 mg budesonide suppositories (2 mg BUS; n = 89 patients), 4 mg BUS (n = 79), 1 g mesalamine suppositories (1 g MES; n = 81), or the combination of 2 mg BUS and 1 g MES (n = 88). The study was performed from November 2013 through July 2015 at 36 study sites in Europe and Russia. The primary end point was the time to resolution of clinical symptoms, defined as the first of 3 consecutive days with a score of 0 for rectal bleeding and stool frequency. The mean time to resolution of symptoms in the 4 mg BUS (29.8 days) and combination of 2 mg BUS and 1 g MES (29.3 days) groups resembled that of the standard 1 g MES treatment (29.2 days), but was significantly longer in the 2 mg BUS group (35.5 days). Furthermore, proportions of patients with deep, clinical, and endoscopic remission, as well as mucosal healing, were similar among the 1 g MES, 4 mg BUS, and combination therapy groups, but significantly lower in the group that received 2 mg BUS. No safety signals were observed, and the patients’ treatment acceptance was high (67%–85% of patients). In a multicenter randomized trial, we found that the efficacy and safety of 4 mg BUS in treatment of active proctitis did not differ significantly from those of 1 g MES. Budesonide suppositories offer an alternative therapy to mesalamine for topical treatment of proctitis. Clinicaltrialsregister.eu no: 2012-003362-41." @default.
• W2800306622 created "2018-05-17" @default.
• W2800306622 creator A5009774393 @default.
• W2800306622 creator A5012621209 @default.
• W2800306622 creator A5017660881 @default.
• W2800306622 creator A5028797683 @default.
• W2800306622 creator A5031092899 @default.
• W2800306622 creator A5031775818 @default.
• W2800306622 creator A5036524512 @default.
• W2800306622 creator A5038825763 @default.
• W2800306622 creator A5042767369 @default.
• W2800306622 creator A5044308235 @default.
• W2800306622 creator A5047884604 @default.
• W2800306622 creator A5050527448 @default.
• W2800306622 creator A5058453235 @default.
• W2800306622 creator A5064256349 @default.
• W2800306622 creator A5064895356 @default.
• W2800306622 creator A5071959037 @default.
• W2800306622 creator A5090917357 @default.
• W2800306622 date "2019-01-01" @default.
• W2800306622 modified "2023-09-30" @default.
• W2800306622 title "Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis" @default.
• W2800306622 cites W1628682521 @default.
• W2800306622 cites W1732758699 @default.
• W2800306622 cites W1964020891 @default.
• W2800306622 cites W1965194899 @default.
• W2800306622 cites W1980308265 @default.
• W2800306622 cites W1990907052 @default.
• W2800306622 cites W2020019737 @default.
• W2800306622 cites W2057498350 @default.
• W2800306622 cites W2065383525 @default.
• W2800306622 cites W2068208094 @default.
• W2800306622 cites W2071970646 @default.
• W2800306622 cites W2076328972 @default.
• W2800306622 cites W2086214319 @default.
• W2800306622 cites W2095573388 @default.
• W2800306622 cites W2102649003 @default.
• W2800306622 cites W2110890905 @default.
• W2800306622 cites W2120204035 @default.
• W2800306622 cites W2122443382 @default.
• W2800306622 cites W2136560153 @default.
• W2800306622 cites W2154052814 @default.
• W2800306622 cites W2166930089 @default.
• W2800306622 cites W2214163214 @default.
• W2800306622 cites W2254842468 @default.
• W2800306622 cites W4210662453 @default.
• W2800306622 cites W4211138554 @default.
• W2800306622 cites W646810701 @default.
• W2800306622 doi "https://doi.org/10.1016/j.cgh.2018.04.027" @default.
• W2800306622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29702300" @default.
• W2800306622 hasPublicationYear "2019" @default.
• W2800306622 type Work @default.
• W2800306622 sameAs 2800306622 @default.
• W2800306622 citedByCount "16" @default.
• W2800306622 countsByYear W28003066222019 @default.
• W2800306622 countsByYear W28003066222020 @default.
• W2800306622 countsByYear W28003066222021 @default.
• W2800306622 countsByYear W28003066222022 @default.
• W2800306622 countsByYear W28003066222023 @default.
• W2800306622 crossrefType "journal-article" @default.
• W2800306622 hasAuthorship W2800306622A5009774393 @default.
• W2800306622 hasAuthorship W2800306622A5012621209 @default.
• W2800306622 hasAuthorship W2800306622A5017660881 @default.
• W2800306622 hasAuthorship W2800306622A5028797683 @default.
• W2800306622 hasAuthorship W2800306622A5031092899 @default.
• W2800306622 hasAuthorship W2800306622A5031775818 @default.
• W2800306622 hasAuthorship W2800306622A5036524512 @default.
• W2800306622 hasAuthorship W2800306622A5038825763 @default.
• W2800306622 hasAuthorship W2800306622A5042767369 @default.
• W2800306622 hasAuthorship W2800306622A5044308235 @default.
• W2800306622 hasAuthorship W2800306622A5047884604 @default.
• W2800306622 hasAuthorship W2800306622A5050527448 @default.
• W2800306622 hasAuthorship W2800306622A5058453235 @default.
• W2800306622 hasAuthorship W2800306622A5064256349 @default.
• W2800306622 hasAuthorship W2800306622A5064895356 @default.
• W2800306622 hasAuthorship W2800306622A5071959037 @default.
• W2800306622 hasAuthorship W2800306622A5090917357 @default.
• W2800306622 hasBestOaLocation W28003066221 @default.
• W2800306622 hasConcept C126322002 @default.
• W2800306622 hasConcept C142724271 @default.
• W2800306622 hasConcept C168563851 @default.
• W2800306622 hasConcept C203092338 @default.
• W2800306622 hasConcept C204787440 @default.
• W2800306622 hasConcept C27081682 @default.
• W2800306622 hasConcept C2776136866 @default.
• W2800306622 hasConcept C2776804153 @default.
• W2800306622 hasConcept C2778042862 @default.
• W2800306622 hasConcept C2779134260 @default.
• W2800306622 hasConcept C2779810446 @default.
• W2800306622 hasConcept C2780479503 @default.
• W2800306622 hasConcept C2781074409 @default.
• W2800306622 hasConcept C535046627 @default.
• W2800306622 hasConcept C71924100 @default.
• W2800306622 hasConcept C90924648 @default.
• W2800306622 hasConcept C98274493 @default.
• W2800306622 hasConceptScore W2800306622C126322002 @default.
• W2800306622 hasConceptScore W2800306622C142724271 @default.
• W2800306622 hasConceptScore W2800306622C168563851 @default.

• next